• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Shanghai International Conference on Laser Medicine and Surgery >Experimental and Clinical Studies on Transmyocardial Laser Revascularization (TMLR)
【24h】

Experimental and Clinical Studies on Transmyocardial Laser Revascularization (TMLR)

机译：跨型激光血运重建（TMLR）的实验与临床研究

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The number of patients with coronary artery disease has been increasing in Japan and several kinds of treatments have been performed to reduce their cardiovascular diseases. In patients with small branches, or diffuse stenotic lesions of the coronary arteries, on whom coronary artery bypass grafting(CABG) and percutaneous coronary intervention (PCI) cannot be carried out, it has been hemodynamically demonstrated possible to supply arterial blood from the left ventricular cavity to the ischemic myocardium through laser channels. On the basis of excellent experimental studies using mongrel dogs, newly created laser channels 0.2 mm in diameter have been confirmed to be histologically patent even 3 years after transmyocardial revascularization(TMLR). Thus, this method could be applied as an alternative procedure of transmyocardial revascularization. First clinical procedure of TMLR alone was performed on 55 year-old male patient with severe angina pectoris who had undergone pericardiectomy 7 years ago. He had no candidate for percutaneous coronary intervention, or coronary artery bypass grafting, because his left venticle had severe adhesion to the left lung. Therefore, this method was finally carried out. He is getting well after this surgical intervention. This procedure should be recommended for the patient with end-stage coronary artery disease.
机译：冠状动脉疾病患者的数量在日本越来越多，已经进行了几种治疗以减少其心血管疾病。在患有小分支的患者中，或冠状动脉的弥漫性狭窄病变不能进行冠状动脉旁路接枝（CABG）和经皮冠状动脉干预（PCI），它已被血流动力学证明可以从左心室供应动脉血通过激光通道对缺血性心肌的腔。在使用杂种犬的优异实验研究的基础上，已经确认新产生的激光通道直径为0.2mm，甚至在缩减内容血运重建（TMLR）后3年是组织学专利。因此，该方法可以应用于透射性血运重建的替代程序。仅在55岁的男性患者上进行TMLR的第一次临床程序，患有严重的心绞痛7年前经历了心包切除术。他没有经皮冠状动脉介入的候选者，或冠状动脉旁路嫁接，因为他的左腹部对左肺有严重的粘附性。因此，最终进行该方法。这种手术干预后他越来越厉害。应建议使用终级冠状动脉疾病的患者进行该程序。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号